Telcon RF Pharmaceutical

At a glance

Telcon RF Pharmaceutical filed 53 disclosures in the last 12 months, including 6 5% holder, 4 insider, 3 issuance and 2 contract. The most recent key filing was on Oct 26: Worth 8.3% of last year's revenue, over about 5 months.

Revenue for 2025 was ₩43.2B, up 14% on 2024. Operating margin was 1.7% against -0.2% a year earlier. Debt was 44% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩38.6B and operating loss of ₩2.2B.

The 2025 annual report lists 133 employees with an average tenure of 4.8 years and average pay of ₩55.3M, #1206 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩61M each on average. It paid no cash dividend for 2025. (주)뉴온 and related parties held 17.78% at year end.

Of 1 recent 5%+ holder report, 0 raised and 1 cut a stake; the largest stake reported was 7.84% on Oct 12.

From the 2025 annual report

Staff: 133 (69 men, 64 women), of whom 10 on fixed-term contracts. Total pay for the year: ₩7.4B. Directors and auditors: 9, paid ₩548M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)뉴온 holds 15.67%; with 1 related party the group holds 17.78% of common shares at year end (from 23.58% at the start of the year).

Auditor: 동성회계법인 (구. 동아송강회계법인) · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

2 new supply contracts worth 14% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports